Neuroactive steroids in schizophrenia

Canadian Journal of Psychiatry

Volumn 50, Issue 11, 2005, Pages 695-702

  Shulman, Yanina ^a   Tibbo, Philip G ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antipsychotics; DHEA; GABAA receptors; Neuroactive steroids; NMDA receptors; Schizophrenia

Indexed keywords

3BETA,5BETA TETRAHYDROPROGESTERONE; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; ALDOSTERONE; ANDROSTANOLONE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CLOZAPINE; CORTICOSTEROID; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NEUROTRANSMITTER; OLANZAPINE; PRASTERONE; PRASTERONE SULFATE; PREGNENOLONE SULFATE; RISPERIDONE; STEROID; STEROID HORMONE; UNCLASSIFIED DRUG;

ANXIETY DISORDER; CLINICAL TRIAL; DEPRESSION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; HUMAN; MEDICAL RESEARCH; MENTAL DISEASE; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SCHIZOPHRENIA; TRANQUILIZING ACTIVITY;

EID: 31744438841     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674370505001109     Document Type: Review

References (53)

1. Abi-Dargham A, Moore H. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 2003;9:404-16.
2. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988;240:889-95.
3. Selye H. Anesthetic effects of steroid hormones. Proc Soc Exp Biol Med 1941;46:116-21.
4. Selye H. The antagonism between steroid hormones and pentamethylentetrazole (metrazol). J Lab Clin Med 1942;27:1051-3.
5. Paul SM, Purdy RH. Neuroactive steroids. FASEB J 1992;6:2311-22.
6. Rupprecht R, Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 1999;22:410-16.
7. Hojo Y, Hattori T-a, Enami T, Furukawa A, Suzuki K, Ishii H-t, and others. Adult male rat hippocampus synthesizes estradiol from pregnenolone by P45017 abd p450 aromatase localized in neurons. Proc Natl Acad Sci 2004;101:865-70.
8. Stoffel-Wagner B. Neurosteroid metabolism in the human brain. Eur J Endocrinol 2001;145:669-79.
9. Stoffel-Wagner B. Neurosteroid biosynthesis in the human brain and its clinical implications. Ann N Y Acad Sci 2003;1007:64-78.
10. O'Dell LE, Alomary AA, Vallée M, Koob GF, Fitzgerald RL, Purdy RH. Ethanol-induced increases in neuroactive steroids in the rat brain and plasma are absent in adrenalectomized and gonadectomized rats. Eur J Pharmacol 2004;484:241-7.
11. Rupprecht R, Reul JM, Trapp T, van Steensel B, Wetzel C, Damm K, and others. Progesterone receptor-mediated effects of neuroactive steroids. Neuron 1993;11:523-30.
12. Rupprecht R. The neuropsychopharmacological potential of neuroactive steroids. J Psychiar Rest 1997;31:297-314.
13. Rupprecht R, Holsboer F. Neuroactive steroids in neuropsychopharmacology. Int Rev Neurobiol 2001;46:461-77.
14. Follesa P, Concas A, Porcu P, Sanna E, Serra M, Mostallino MC, and others. Role of allopregnanolone in the regulation of GABAA receptor plasticity during long-term exposure to and withdrawal from progesterone. Brain Res Brain Res Rev 2001;37:81-90.
15. Zinder O, Dar DE. Neuroactive steroids: their mechanism of action and their function in the stress response. Acta Physiol Scand 1999;167:181-8.
16. Macdonald RL, Olsen RW. GABAA receptor channels. Annu Rev Neurosci 1994;17:569-602.
17. Twyman RE, Macdonald RL. Neurosteroid regulation of GABAA receptor single-channel kinetic properties of mouse spinal cord neurons in culture. J Physiol 1992;456:215-45.
18. Le Mellédo J-M, Baker GB. Neuroactive steroids and anxiety disorders. J Psychiatry Neurosci 2002;27:161-5.
19. Lundgren P, Strömberg J, Bäckström T, Wang M. Allopregnanolone-stimulated GABA-mediated chloride ion flux is inhibited by 3 -hydroxy-5 -pregnan-20-one (isoallopregnanolone). Brain Res 2003;982:45-53.
20. Prince RJ, Simmonds MA. 5-beta-Pregnan-3-beta-ol-20-one, a specific antagonist at the neurosteroid site of the GABAA receptor-complex. Neurosci Lett 1992;135:273-5.
21. Prince RJ, Simmonds MA. Differential antagonism by epipregnanolone of alphaxalone and pregnanolone potentiation of [3H]flunitrazepam binding suggests more than one class of binding site for steroids at GABAA receptors. Neuropharmacology 1993;32:59-63.
22. Nestler EJ, Hyman SE, Malenka RC, editor. Molecular neuropharmacology: a foundation for clinical neuroscience. New York (NY): McGraw-Hill; 2001.
23. Imamura M, Prasad C. Modulation of GABA-gated chloride influx in the brain by dehydroepiandrosterone and its metabolites. Biochem Biophys Res Commun 1998;243:771-5.
24. Park-Chung M, Malayev A, Purdy RH, Gibbs TT, Farb DH. Sulfated and unsulfated steroids modulate gamma-aminobutyric acidA receptor function through distinct sites. Brain Res 1999;830:72-87.
25. Baulieu EE, Robel P. Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) as neuroactive neurosteroids. Proc Natl Acad Sci USA 1998;95:4089-91.
26. Rupprecht R. Neuroactive steroids: mechanism of action and neuropsychopharmacological properties. Psychoneuroendocrinology 2003;28:139-68.
27. Tourney G, Erb JL. Temporal variation in androgens and stress hormones in control and schizophrenic subjects. Biol Psychiatry 1979;14:395-404.
28. Marx CE, Trost WT, Shampine LJ, Lieberman JA, Morrow AL, Thakore JH. Neuroactive steroids in schizophrenia: relevance to symptoms and therapeutics. Biol Psychiatry 2004;55(Suppl 8):171.
29. Oades RD, Schepker R. Serum gonadal steroids in young schizophrenic patients. Psychoneuroendochrinology 1994;19:373-85.
30. Shirayama Y, Hashimoto K, Suzuki Y, Higuchi T. Correlation of plasma neurosteroids to the severity of negative symptoms in male patients with schizophrenia. Schizophrenia Res 2002;58:69-74.
31. Ritsner M, Maayan R, Gibel A, Strous RD, Modai I, Weizman A. Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. Eur Neuropsychopharmacol 2004;14:267-73.
32. Breier A, Buchanan RW. The effects of metabolic stress on plasma progesterone levels in healthy volunteers and schizophrenic patients. Life Sci 1992;51:1527-34.
33. Prior TI, Tibbo PG, Purdon SE. Elevated progesterone levels correlate with symptom severity in males newly diagnosed with schizophrenia or schizophreniform disorder. Proceeding of the Canadian College of Neuropsychopharmacology; June, 2003; Montreal (QC).
34. Taherianfard M, Shariaty M. Evaluation of serum steroid hormones in schizophrenic patients. Indian J Med Sci 2004;58:3-9.
35. Tibbo P, Swainson J, Chue P, Le Mellédo J-M. Prevalence and relationship to delusions and hallucinations of anxiety disorders in schizophrenia. Depress Anxiety 2003;17:65-72.
36. Barbaccia MD, Affricano D, Purdy RH, Maciocco E, Spiga F, Biggio G. Clozapine, but not haloperidol, increases brain concentrations of neuroactive steroids in the rat. Neuropsychopharmacology 2001;25:489-97.
37. Marx CE, Duncan GE, Gilmore JH, Lieberman JA, Morrow AL. Olanzapine increases allopregnanolone in the rat cerebral cortex. Biol Psychiatry 2000;47:1000-4.
38. Marx CE, VanDoren MJ, Duncan GE, Lieberman JA, Morrow AL. Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacol 2003;28:1-13.
39. Nechmad A, Maayan R, Ramadan E, Morad O, Poyurovsky M, Weizman A. Clozapine decreases rat brain dehydroepiandrosterone and dehydroepiandrosterone sulfate levels. Eur Neuropsychopharmacol 2003;13:29-31.
40. Benes FM, Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 2001;25:1-27.
41. Motzo C, Porceddu ML, Maira G, Flore G, Concas A, Dazzi L, and others. Inhibition of basal and stress-induced dopamine release in the cerebral cortex and nucleus accumbens of freely moving rats by the neurosterid allopregnanolone. J Psychopharmacol 1996;10:266-72.
42. Khisti RT, Mandhane SN, Chopde CT. The neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one induces catalepsy in mice. Neurosci Lett 1998;251:85-8.
43. Khisti RT, Deshpande LS, Chopde CT. The neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one affects dopamine-mediated behavior in rodents. Psychopharmacology (Berl) 2002;161:120-8.
44. Ugale RR, Hirani K, Morelli M, Chopde CT. Role of Neuroactive Steroid Allopregnanolone in Antipsychotic-like Action of Olanzapine in Rodents. Neuropsychopharmacology 2004:29:1597-609.
45. Wen S, Dong K, Onolfo JP, Vincens M. Treatment with dehydroepiandrosterone sulfate increases NMDA receptors in hippocampus and cortex. Eur J Pharmacol 2001;430:373-4.
46. Majewska MD. Neurosteroid antagonists of the GABAA receptors. In: Baulieu E-E, Robel P, Schumacher M, editors. Neurosteroids: a new regulatory function in the nervous system. Totawa (NJ): Humana Press Inc; 1999. p 155-66.
47. Miyamoto S, LaMantia AS, Duncan GE, Sullivan P, Gilmore JH, Lieberman JA. Recent advances in the neurobiology of schizophrenia. Mol Interv 2003;3:27-39.
48. Harris DD, Wolkowitz OM, Reus VI. Movement disorder, memory, psychiatric symptoms and serum DHEA levels in schizophrenic and schizoaffective patients. World J Biol Psychiatry 2001;2:99-102.
49. Strauss EB, Sands DE, Robinson AM, Tandall WJ, Stevenson WAH. Use of dehydroepiandrosterone in psychiatric treatment: a preliminary survey. Br Med J 1952;2:64-6.
50. Strous RD, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, and others. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry 2003;60:133-41.
51. Hallonquist JD, Seeman MV, Lang M, Rector NA. Variation in symptom severity over the menstrual cycle of schizophrenics. Biol Psychiatry 1993;33:207-9.
52. Häfner H, Riecher-Rössler A, An Der Heiden W, Maurer K, Fätkenheuer B, Löffler W. Generating and testing a causal explanation of the gender differences in age at first onset of schizophrenia. Psychol Med 1993;23:925-40.
53. Rupprecht R, Koch M, Montkowski A, Lancel M, Faulhaber J, Harting J, and others. Assessment of neuroleptic-like properties of progesterone. Psychopharmacology (Berl) 1999;143:29-38.